

DAFTAR PUSTAKA

1. Torres A, Cilloniz C, Niederman MS, Menéndez R, Chalmers JD, Wunderink RG, et al. Pneumonia. *Nat Rev Dis Prim.* 2021;7(1).
2. Lanks CW, Musani AI, Hsia DW. Community-acquired Pneumonia and Hospital-acquired Pneumonia. *Med Clin North Am.* 2019;103(3):487–501.
3. Burhan E, Isbaniah F, Hatim F, Djaharuddin I, Soedarsono S, Harsini H, et al. *Pneumonia Komunitas: Pedoman Diagnosis dan Penatalaksanaan Di Indonesia. Revisi 2.* Jakarta: Perhimpunan Dokter Paru Indonesia; 2022.
4. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet (London, England).* 2020;396(10258):1204–22.
5. Regunath H, Oba Y. Community-Acquired Pneumonia [Internet]. *StatPearls [Internet].* 2022. Tersedia pada: https://www.ncbi.nlm.nih.gov/books/NBK430749/#_NBK430749_pubdet_
6. Lindenauer PK, Strait KM, Grady JN, Ngo CK, Parisi ML, Metersky M, et al. Variation in the Diagnosis of Aspiration Pneumonia and Association with Hospital Pneumonia Outcomes. *Ann Am Thorac Soc.* 2018;15(5):562–9.
7. Cillóniz C, Torres A, Niederman MS. Management of pneumonia in critically ill patients. *BMJ.* 2021;375:e065871.
8. Abbafati C, Abbas KM, Abbasi-Kangevari M, Abd-Allah F, Abdelalim A, Abdollahi M. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet.* 2020;396(10258):1204–22.
9. Shi T, Denouel A, Tietjen AK, Lee JW, Falsey AR, Demont C, et al. Global and Regional Burden of Hospital Admissions for Pneumonia in Older Adults: A Systematic Review and Meta-Analysis. *J Infect Dis.* 2020;222(Suppl 7):S570–6.
10. Ho J, Ip M. Antibiotic-Resistant Community-Acquired Bacterial Pneumonia. *Infect Dis Clin North Am.* 2019;33(4):1087–103.

11. Azar MM. A Diagnostic Approach to Fungal Pneumonia: An Infectious Diseases Perspective. *Chest*. 2023;
12. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet*. 2022;399(10325):629–55.
13. Intharuksa A, Arunotayanun W, Yooiin W, Sirisa-ard P. A Comprehensive Review of *Andrographis paniculata* (Burm. f.) Nees and Its Constituents as Potential Lead Compounds for COVID-19 Drug Discovery. *Molecules*. 2022;27(14).
14. Purwanti S. Penanaman Sambiloto [Internet]. Cyber Extension Pusluhtan Kementan. 2023. Tersedia pada: <http://cybex.pertanian.go.id/detail-print.php?id=52898>
15. Sah SK, Rasool U, Hemalatha S. *Andrographis paniculata* extract inhibit growth, biofilm formation in multidrug resistant strains of *Klebsiella pneumoniae*. *J Tradit Complement Med*. 2020;10(6):599–604.
16. Zhou Q, Tang M, Zhang X, Lu J, Tang X, Gao Y. Detection of AmpC β -lactamases in gram-negative bacteria. *Heliyon*. 2022;8(12):e12245.
17. Wanaratna K, Leethong P, Inchai N, Chueawiang W, Sriraksa P, Tabmee A, et al. Efficacy and Safety of *Andrographis Paniculata* Extract in Patients with Mild COVID-19: A Randomized Controlled Trial. *Arch Intern Med Res*. 2022;05(03):3–7.
18. Banerjee S, Kar A, Mukherjee PK, Haldar PK, Sharma N, Katiyar CK. Immunoprotective potential of Ayurvedic herb Kalmegh (*Andrographis paniculata*) against respiratory viral infections – LC–MS/MS and network pharmacology analysis. *Phytochem Anal*. 2021;32(4):629–39. Tersedia pada: <https://doi.org/10.1002/pca.3011>
19. Ruiz-González A, Utrillo L, Bielsa S, Falguera M, Porcel JM. The Diagnostic Value of Serum C-Reactive Protein for Identifying Pneumonia in Hospitalized Patients with Acute Respiratory Symptoms. Duncan M, editor. *J Biomarkers*. 2016;2016:2198745.

20. Ito A, Ishida T. Diagnostic markers for community-acquired pneumonia. *Ann Transl Med* Vol 8, No 9 (May 14, 2020) *Ann Transl Med*. 2020; Tersedia pada: <https://atm.amegroups.org/article/view/37320>
21. Salsabela R, Widyastiti NS, Retnoningrum D, Ariosta A, Susilaningsih N. Effects of *Andrographis paniculata* Leaf Extract on C-Reactive Protein and Serum Ferritin in Lipopolysaccharide-Induced Sepsis Model Rat. *J Kedokt Diponegoro (Diponegoro Med Journal)*. 2023;12(3):131–6.
22. Lee H, Kim I, Kang BH, Um SJ. Prognostic value of serial neutrophil-to-lymphocyte ratio measurements in hospitalized community-acquired pneumonia. *PLoS One*. 2021;16(4):1–12.
23. Song M, Graubard BI, Rabkin CS, Engels EA. Neutrophil-to-lymphocyte ratio and mortality in the United States general population. *Sci Rep*. 2021;11(1):464.
24. Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to Lymphocyte Ratio: An Emerging Marker of the Relationships between the Immune System and Diseases. *Int J Mol Sci*. 2022;23(7).
25. Zhu T, Zhang W, Xiao M, Chen H, Jin H. Protective role of andrographolide in bleomycin-induced pulmonary fibrosis in mice. *Int J Mol Sci*. 2013;14(12):23581–96.
26. Tanwettayanont J, Piriyananusorn N, Sangsoi L, Boonsong B, Sunpapoa C, Tanamatayarat P, et al. Use of *Andrographis paniculata* (Burm.f.) Wall. ex Nees and risk of pneumonia in hospitalised patients with mild coronavirus disease 2019: A retrospective cohort study. *Front Med*. 2022;9:947373.
27. Shi H, Guo W, Zhu H, Li M, Ung COL, Hu H, et al. Cost-Effectiveness Analysis of Xiyanning Injection (Andrographolide Sulfonate) for Treatment of Adult Community Acquired Pneumonia: A Retrospective, Propensity Score-Matched Cohort Study. Nakae H, editor. *Evidence-Based Complement Altern Med*. 2019;2019:4510591.
28. Reviono. *Pneumonia; Adakah tempat untuk pemberian antinflamasi*. Harsini H, editor. Surakarta: UNS Press; 2017. p. 60–75.

29. National Institute for Health and Care Excellent. Pneumonia in adults: diagnosis and management. NICE Guidel. 2022;(December 2014):1–18. Tersedia pada: <http://www.nice.org.uk/guidance/cg191>
30. Rothberg MB. Community-Acquired Pneumonia. *Ann Intern Med.* 2022;175(4):ITC49–64.
31. Cherniack NS. Pulmonary Pathophysiology. Vol. 131, *Annals of Internal Medicine.* 1999. 399 hal.
32. Eshwara VK, Mukhopadhyay C, Rello J. Community-acquired bacterial pneumonia in adults: An update. *Indian J Med Res.* 2020;151(4):287–302.
33. Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. *Pneumonia.* 2020;12(1):11. Tersedia pada: <https://doi.org/10.1186/s41479-020-00074-3>
34. Lanks CW, Musani AI, Hsia DW. Community-acquired Pneumonia and Hospital-acquired Pneumonia. *Med Clin North Am.* 2019;103(3):487–501. Tersedia pada: <https://doi.org/10.1016/j.mcna.2018.12.008>
35. Loscalzo J. Pneumonia. In: *Harrison's Pulmonary and Critical Care Medicine.* New York: The McGraw-Hill Companies; 2010. hal. 99–100.
36. Quinton LJ, Walkey AJ, Mizgerd JP. Integrative Physiology of Pneumonia. *Physiol Rev.* 2018;98(3):1417–64.
37. Nishimoto AT, Rosch JW, Tuomanen EI. Pneumolysin: Pathogenesis and Therapeutic Target. *Front Microbiol.* 2020;11(July):1–10.
38. von Hoven G, Qin Q, Neukirch C, Husmann M, Hellmann N. Staphylococcus aureus α -toxin: small pore, large consequences. *Biol Chem.* 2019;400(10):1261–76.
39. Murphy K, Weaver C. *Janeway's immunobiology.* 9th ed. New York, NY: Garland Science/Taylor & Francis Group, LLC; 2017.
40. Allard B, Panariti A, Martin JG. Alveolar Macrophages in the Resolution of Inflammation, Tissue Repair, and Tolerance to Infection. *Front Immunol.* 2018;9:1777.

41. Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. *J Clin Invest*. 2018;128(7):2657–69.
42. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. *Am J Respir Crit Care Med*. 2019;200(7):E45–67.
43. Cilloniz C, Torres A. Community-acquired pneumonia (non Covid-19) [Internet]. *BMJ Best Practice*. 2023. Tersedia pada: <https://bestpractice.bmj.com/topics/en-us/17/diagnosis-approach>
44. Jain V, Vashisht R, Yilmaz G, Bhardwaj A. Pneumonia Pathology [Internet]. *StartPearls*. 2022. Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK526116/#article-27364.s7>
45. Niederman MS. Imaging for the Management of Community-Acquired Pneumonia: What to Do if the Chest Radiograph Is Clear. *Chest*. 2018;153(3):583–5.
46. D’Amato M, Rea G, Carnevale V, Grimaldi MA, Saponara AR, Rosenthal E, et al. Assessment of thoracic ultrasound in complementary diagnosis and in follow up of community-acquired pneumonia (cap). *BMC Med Imaging*. 2017;17(1):52.
47. Long L, Zhao H-T, Zhang Z-Y, Wang G-Y, Zhao H-L. Lung ultrasound for the diagnosis of pneumonia in adults: A meta-analysis. *Medicine (Baltimore)*. 2017;96(3):e5713.
48. Sungurlu S, Balk RA. The Role of Biomarkers in the Diagnosis and Management of Pneumonia. *Clin Chest Med*. 2018;39(4):691–701.
49. Ranzani OT, Coelho L, Torres A. Biomarkers in community-acquired pneumonia: Can we do better by using them correctly? *J Bras Pneumol*. 2019;45(4):10–2.
50. Ito A, Ishida T. Diagnostic markers for community-acquired pneumonia. *Ann Transl Med*. 2020;8(9):609–609.
51. Manullang D, Keliat EN, Abidin A. Procalcitonin level is correlated with community pneumonia severity. *Cermin Dunia Kedokt*. 2018;45(9):647–51.

52. Ebrahimi F, Giaglis S, Hahn S, Blum CA, Baumgartner C, Kutz A, et al. Markers of neutrophil extracellular traps predict adverse outcome in community-acquired pneumonia: secondary analysis of a randomised controlled trial. *Eur Respir J*. 2018;51(4).
53. Spoorenberg SMC, Vestjens SMT, Rijkers GT, Meek B, van Moorsel CHM, Grutters JC, et al. YKL-40, CCL18 and SP-D predict mortality in patients hospitalized with community-acquired pneumonia. *Respirology*. 2017;22(3):542–50.
54. Zhu C, Zhou Y, Zhu J, Liu Y, Sun M. NACHT, LRR, and PYD domains-containing Protein 3 and LL-37: prognostic value of new biomarkers in community-acquired pneumonia. *J Bras Pneumol publicacao Of da Soc Bras Pneumol e Tisiologia*. 2019;45(4):e20190001.
55. Marhanan IA, Amin M, Permatasari A, Rosyid AN. *Buku Ajar Paru*. Surabaya: Airlangga University Press; 2022.
56. Patel S. Calculated decisions: PSI/PORT score: pneumonia severity index for community-acquired pneumonia. *Emerg Med Pract*. 2021;23(Suppl 2):CD2–3.
57. Rider AC, Frazee BW. Community-Acquired Pneumonia. *Emerg Med Clin North Am*. 2018;36(4):665–83.
58. Modi AR, Kovacs CS. Community-acquired pneumonia: Strategies for triage and treatment. *Cleve Clin J Med*. 2020;87(3):145–51.
59. Torres A, Chalmers JD, Dela Cruz CS, Dominedò C, Kollef M, Martin-Loeches I, et al. Challenges in severe community-acquired pneumonia: a point-of-view review. *Intensive Care Med*. 2019;45(2):159–71.
60. Tansarli GS, Mylonakis E. Systematic Review and Meta-analysis of the Efficacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia in Adults. *Antimicrob Agents Chemother*. 2018;62(9).
61. Letter TM. Antibacterial Drugs for Community-Acquired Pneumonia. *Med Lett*. 2021;63.

62. Metlay JP, Waterer GW. Treatment of Community-Acquired Pneumonia During the Coronavirus Disease 2019 (COVID-19) Pandemic. Vol. 173, *Annals of internal medicine*. United States; 2020. hal. 304–5.
63. Wunderink RG. Guidelines to Manage Community-Acquired Pneumonia. *Clin Chest Med*. 2018;39(4):723–31.
64. Schoch C. NCBI Taxonomy: a comprehensive update on curation, resources and tools. [Internet]. NCBI. 2020. Tersedia pada: <https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=175694>
65. Saras T. *Sambiloto: Manfaat dan Khasiat Tumbuhan Obat Indonesia*. Tiram Media; 2023.
66. Chauhan ES, Sharma K, Bist R. *Andrographis paniculata*: A review of its phytochemistry and pharmacological activities. *Res J Pharm Technol*. 2019;12(2):891–900.
67. Kandanur SGS, Tamang N, Golakoti NR, Nanduri S. Andrographolide: A natural product template for the generation of structurally and biologically diverse diterpenes. *Eur J Med Chem*. 2019;176:513–33.
68. Pandit S, Kanjilal S, Awasthi A, Chaudhary A, Banerjee D, Bhatt BN, et al. Evaluation of herb-drug interaction of a polyherbal Ayurvedic formulation through high throughput cytochrome P450 enzyme inhibition assay. *J Ethnopharmacol*. 2017;197:165–72.
69. Panossian A, Hovhannisyanyan A, Mamikonyan G, Abrahamian H, Hambardzumyan E, Gabrielian E, et al. Pharmacokinetic and oral bioavailability of andrographolide from *Andrographis paniculata* fixed combination Kan Jang in rats and human. *Phytomedicine*. 2000;7(5):351–64.
70. Songvut P, Rangkadilok N, Pholphana N, Suriyo T, Panomvana D, Puranajoti P, et al. Comparative pharmacokinetics and safety evaluation of high dosage regimens of *Andrographis paniculata* aqueous extract after single and multiple oral administration in healthy participants [Internet]. Vol. 14, *Frontiers in Pharmacology*. 2023. Tersedia pada: <https://www.frontiersin.org/articles/10.3389/fphar.2023.1230401>

71. Tumewu L, Pamungkas I, Ilmi H, Hafid A, Tantular I, Suciati S, et al. The Role of Andrographolide in *Andrographis paniculata* as a Potential Analgesic for Herbal Medicine based Drug Development. *Res J Pharm Technol*. 2021;14(12):6269–74.
72. Zeng B, Wei A, Zhou Q, Yuan M, Lei K, Liu Y, et al. Andrographolide: A review of its pharmacology, pharmacokinetics, toxicity and clinical trials and pharmaceutical researches. *Phyther Res*. 2022;36(1):336–64. Tersedia pada: <https://doi.org/10.1002/ptr.7324>
73. Zhang Q, Cui Q. Biodistribution of andrographolide to assess the interior-exterior relationship between the lung and intestine using microPET. *Thorac cancer*. 2020;11(11):3365–74.
74. Godugu D, Rupula K, Sashidhar RB. Binding Studies of Andrographolide with Human Serum Albumin: Molecular Docking, Chromatographic and Spectroscopic Studies. *Protein Pept Lett*. 2018;25(4):330–8.
75. Yu Z, Chen Z, Li Q, Yang K, Huang Z, Wang W, et al. What dominates the changeable pharmacokinetics of natural sesquiterpene lactones and diterpene lactones: a review focusing on absorption and metabolism. *Drug Metab Rev*. 2021;53(1):122–40.
76. Worasuttayangkurn L, Nakareangrit W, Kwangjai J, Sritangos P, Pholphana N, Watcharasit P, et al. Acute oral toxicity evaluation of *Andrographis paniculata*-standardized first true leaf ethanolic extract. *Toxicol reports*. 2019;6:426–30.
77. Makmur T, Siregar FA, Siregar S, Lubis IA, Bestari R, Zein U. Open Clinical Trial of Sambiloto (*Andrographis paniculata*) Ethanolic Extract Capsules in Treatment of Malaria Patients in Batubara District, Indonesia. *Med Arch (Sarajevo, Bosnia Herzegovina)*. 2022;76(6):419–25.
78. Saxena RC, Singh R, Kumar P, Yadav SC, Negi MPS, Saxena VS, et al. A randomized double blind placebo controlled clinical evaluation of extract of *Andrographis paniculata* (KalmCold™) in patients with uncomplicated upper respiratory tract infection. *Phytomedicine*. 2010;17(3):178–85.

79. Wanaratna K, Leethong P, Inchai N, Chueawiang W, Sriraksa P, Tabmee A, et al. Efficacy and safety of *Andrographis paniculata* extract in patients with mild COVID-19: A randomized controlled trial. medRxiv. 2021;2021.07.08.21259912.
80. Hossain S, Urbi Z, Karuniawati H, Mohiuddin RB, Qrimida AM, Allzrag AMM, et al. *Andrographis paniculata* (Burm. f.) wall. ex nees: An updated review of phytochemistry, antimicrobial pharmacology, and clinical safety and efficacy. Life. 2021;11(4):1–39.
81. Parveen R, Parveen B, Parveen A, Ahmad S. *Andrographis paniculata*: From Traditional to Nano Drug for Cancer Therapy. In 2019. hal. 317–45.
82. Akilandeswari G, Anand AV, Sampathkumar P, Moorthi PV, Preethi B. A prospective review on phyto-pharmacological aspects of *Andrographis paniculata*. Syst Rev Pharm. 2019;10(1):15–9.
83. Zhang T, Zhu L, Li M, Hu Y, Zhang E, Jiang Q, et al. Inhalable *Andrographolide*- β -cyclodextrin Inclusion Complexes for Treatment of *Staphylococcus aureus* Pneumonia by Regulating Immune Responses. Mol Pharm. 2017;14(5):1718–25.
84. Banerjee M, Parai D, Chattopadhyay S, Mukherjee SK. *Andrographolide*: antibacterial activity against common bacteria of human health concern and possible mechanism of action. Folia Microbiol (Praha). 2017;62(3):237–44.
85. Benjaponpitak A, Sawaengtham T, Thaneerat T, Wanaratna K. Effect of *Andrographis paniculata* treatment for patients with early-stage COVID-19 on the prevention of pneumonia : A retrospective cohort study. Arch Intern Med Res. 2023;35–43.
86. Zhang L, Bao M, Liu B, Zhao H, Zhang Y, Ji XY, et al. Effect of *Andrographolide* and Its Analogs on Bacterial Infection: A Review. Pharmacology. 2020;105(3–4):123–34.
87. Markanday A. Acute Phase Reactants in Infections: Evidence-Based Review and a Guide for Clinicians. Open forum Infect Dis. 2015;2(3):ofv098.
88. Nehring SM, Goyal A, Patel BC. C Reactive Protein. In Treasure Island (FL): Statpearls Publisher; 2024.

89. Wang L, Guo W, Wang C, Yang X, Hao Z, Wu S, et al. Dynamic Change of Neutrophil to Lymphocyte Ratios and Infection in Patients with Acute Ischemic Stroke. *Curr Neurovasc Res.* 2020;17(3):294–303.
90. Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. *Bratisl Lek Listy.* 2021;122(7):474–88.
91. Lee T-Y, Chang H-H, Wen C-K, Huang T-H, Chang Y-S. Modulation of thioacetamide-induced hepatic inflammations, angiogenesis and fibrosis by andrographolide in mice. *J Ethnopharmacol.* 2014;158 Pt A:423–30.
92. Burgos RA, Alarcón P, Quiroga J, Manosalva C, Hancke J. Andrographolide, an Anti-Inflammatory Multitarget Drug: All Roads Lead to Cellular Metabolism. *Molecules.* 2020;26(1).
93. Schweizer ML, Braun BI, Milstone AM. Research Methods in Healthcare Epidemiology and Antimicrobial Stewardship-Quasi-Experimental Designs. *Infect Control Hosp Epidemiol.* 2016;37(10):1135–40.
94. Dimitrov DM, Rumrill PD. Pretest-posttest designs and measurement of change. *Work.* 2003;20(2):159–65.
95. Cillóniz C, Cardozo C, García-Vidal C. Epidemiology, pathophysiology, and microbiology of community-acquired pneumonia. *Ann Res Hosp.* 2018;2:1–1.
96. Takaki M, Nakama T, Ishida M, Morimoto H, Nagasaki Y, Shiramizu R, et al. High incidence of community-acquired pneumonia among rapidly aging population in Japan: a prospective hospital-based surveillance. *Jpn J Infect Dis.* 2014;67(4):269–75.
97. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. *N Engl J Med.* 2015;373(5):415–27.
98. Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. *Thorax.* 2013;68(11):1057–65.

99. Morimoto K, Suzuki M, Ishifuji T, Yaegashi M, Asoh N, Hamashige N, et al. The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study. *PLoS One*. 2015;10(3):e0122247.
100. Phung DT, Wang Z, Rutherford S, Huang C, Chu C. Body mass index and risk of pneumonia: a systematic review and meta-analysis. *Obes Rev an Off J Int Assoc Study Obes*. 2013;14(10):839–57.
101. Nie W, Zhang Y, Jee SH, Jung KJ, Li B, Xiu Q. Obesity survival paradox in pneumonia: a meta-analysis. *BMC Med*. 2014;12:61.
102. Han D-W, Jung W, Lee KN, Han K, Lee SW, Shin DW. Smoking behavior change and the risk of pneumonia hospitalization among smokers with diabetes mellitus. *Sci Rep*. 2023;13(1):14189. Tersedia pada: <https://doi.org/10.1038/s41598-023-40658-9>
103. Jiang C, Chen Q, Xie M. Smoking increases the risk of infectious diseases: A narrative review. *Tob Induc Dis*. 2020;18(July). Tersedia pada: <https://doi.org/10.18332/tid/123845>
104. Huang Y, Gou R, Diao Y, Yin Q, Fan W, Liang Y, et al. Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy. *J Zhejiang Univ Sci B*. 2014;15(1):58–66.
105. Bahlis L, Diogo L, Fuchs S. Charlson Comorbidity Index and other predictors of in-hospital mortality among adults with community-acquired pneumonia. *J Bras Pneumol*. 2021;47:e20200257.
106. Cichocki M, Baer-Dubowska W, Wierzchowski M, Murias M, Jodynisk-Liebert J. 3,4,5,4'-trans-tetramethoxystilbene (DMU-212) modulates the activation of NF- κ B, AP-1, and STAT3 transcription factors in rat liver carcinogenesis induced by initiation-promotion regimen. *Mol Cell Biochem*. 2014;391(1–2):27–35.
107. Ngwa DN, Pathak A, Agrawal A. IL-6 regulates induction of C-reactive protein gene expression by activating STAT3 isoforms. *Mol Immunol*. 2022;146:50–6.

108. Mohamed GA, Abd-Elrahman MZ, Bahriz R, Albehairy A. Inflammatory cytokine and plasma C-reactive protein response to ketoacidosis in adults with type 1 diabetes: Egyptian multicenter study. *Egypt J Intern Med.* 2020;32(1):10.
109. Lowsby R, Gomes C, Jarman I, Lisboa P, Nee PA, Vardhan M, et al. Neutrophil to lymphocyte count ratio as an early indicator of blood stream infection in the emergency department. *Emerg Med J.* 2015;32(7):531–4.
110. Hidalgo M, Hancke J, Bertoglio J, Burgos R. Andrographolide a New Potential Drug for the Long Term Treatment of Rheumatoid Arthritis Disease. In: *Innovative Rheumatology.* 2013. hal. 256–79.
111. Bao Z, Guan S, Cheng C, Wu S, Wong SH, Michael Kemeny D, et al. A novel antiinflammatory role for andrographolide in asthma via inhibition of the nuclear factor- κ b pathway. *Am J Respir Crit Care Med.* 2009;179(8):657–65.
112. Guan SP, Tee W, Ng DSW, Chan TK, Peh HY, Ho WE, et al. Andrographolide protects against cigarette smoke-induced oxidative lung injury via augmentation of Nrf2 activity. *Br J Pharmacol.* 2013;168(7):1707–18.
113. Calabrese C, Berman SH, Babish JG, Ma X, Shinto L, Dorr M, et al. A phase I trial of andrographolide in HIV positive patients and normal volunteers. *Phytother Res.* 2000;14(5):333–8.
114. Suter-Widmer I, Christ-Crain M, Zimmerli W, Albrich W, Mueller B, Schuetz P, et al. Predictors for length of hospital stay in patients with community-acquired Pneumonia: Results from a Swiss Multicenter study. *BMC Pulm Med.* 2012;12(1):21.
115. Sitompul PA, Indriani R, Maemun S, Rusli A, Sundari T, Marlina R, et al. Length of stay of pneumonia patients associated with comorbid and complications factors in referral National Infectious Diseases Hospital. *Tanzan J Health Res.* 2023;24(1):1–5.

116. Menéndez R, Ferrando D, Vallés JM, Martínez E, Perpiñá M. Initial risk class and length of hospital stay in community-acquired pneumonia. *Eur Respir J*. 2001;18(1):151–6.
117. Schober P, Schwarte LA. Correlation coefficients: Appropriate use and interpretation. *Anesth Analg*. 2018;126(5):1763–8.
118. Farah R, Khamisy-Farah R, Makhoul N. Consecutive Measures of CRP Correlate with Length of Hospital Stay in Patients with Community-Acquired Pneumonia. *Isr Med Assoc J*. 2018;20(6):345–8.
119. Li LL, Yang YQ, Qiu M, Wang L, Yuan HL, Zou RC. The clinical significance of neutrophil-lymphocyte ratio in patients treated with hemodialysis complicated with lung infection. *Med (United States)*. 2021;100(29):E26591.
120. Menéndez R, Cremades MJ, Martínez-Moragón E, Soler JJ, Reyes S, Perpiñá M. Duration of length of stay in pneumonia: Influence of clinical factors and hospital type. *Eur Respir J*. 2003;22(4):643–8.
121. Liu X, Zhou H, Zhou Y, Wu X, Zhao Y, Lu Y, et al. Risk factors associated with disease severity and length of hospital stay in COVID-19 patients. Vol. 81, *The Journal of infection*. England; 2020. hal. e95–7.
122. Li X, Yuan W, Wu J, Zhen J, Sun Q, Yu M. Andrographolide, a natural anti-inflammatory agent: An Update. *Front Pharmacol*. 2022;13:920435.
123. Calabró P, Willerson JT, Yeh ETH. Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells. *Circulation*. 2003;108(16):1930–2.
124. Malarvizhi KA. Review on the Various Drug Delivery Systems of Andrographolide. *Phytopharm Drug Deliv Approaches*. 2019;2–13.
125. Loureiro Damasceno JP, Silva da Rosa H, Silva de Araújo L, Jacometti Cardoso Furtado NA. Andrographis paniculata Formulations: Impact on Diterpene Lactone Oral Bioavailability. *Eur J Drug Metab Pharmacokinet*. 2022;47(1):19–30.

126. Adiguna SP, Pangabebean JA, Atikana A, Untari F, Izzati F, Bayu A, et al. Antiviral Activities of Andrographolide and Its Derivatives: Mechanism of Action and Delivery System. *Pharmaceuticals (Basel)*. 2021;14(11).
127. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of 'overspill' of inflammatory mediators from the lungs? Review of the evidence. *Thorax*. 2010;65(10):930 LP – 936. Tersedia pada: <http://thorax.bmj.com/content/65/10/930.abstract>
128. Lohmann-Matthes ML, Steinmüller C, Franke-Ullmann G. Pulmonary macrophages. *Eur Respir J*. 1994;7(9):1678–89.
129. van Eeden SF, Tan WC, Suwa T, Mukae H, Terashima T, Fujii T, et al. Cytokines involved in the systemic inflammatory response induced by exposure to particulate matter air pollutants (PM(10)). *Am J Respir Crit Care Med*. 2001;164(5):826–30.
130. Guo X, Ma L. Inflammation in coronary artery disease-clinical implications of novel HDL-cholesterol-related inflammatory parameters as predictors. *Coron Artery Dis*. 2023;34(1):66–77.
131. Schroer AK, Merryman WD. Mechanobiology of myofibroblast adhesion in fibrotic cardiac disease. *J Cell Sci*. 2015;128(10):1865–75.
132. Yoshida T, Friehs I, Mummidi S, del Nido PJ, Addulnour-Nakhoul S, Delafontaine P, et al. Pressure overload induces IL-18 and IL-18R expression, but markedly suppresses IL-18BP expression in a rabbit model. IL-18 potentiates TNF- α -induced cardiomyocyte death. *J Mol Cell Cardiol*. 2014;75:141–51.
133. Honsho S, Nishikawa S, Amano K, Zen K, Adachi Y, Kishita E, et al. Pressure-mediated hypertrophy and mechanical stretch induces IL-1 release and subsequent IGF-1 generation to maintain compensative hypertrophy by affecting Akt and JNK pathways. *Circ Res*. 2009;105(11):1149–58.
134. Sager HB, Heidt T, Hulsmans M, Dutta P, Courties G, Sebas M, et al. Targeting Interleukin-1 β Reduces Leukocyte Production After Acute Myocardial Infarction. *Circulation*. 2015;132(20):1880–90.

135. Žiemytė M, Rodríguez-Díaz JC, Ventero-Martín MP, Mira A, Ferrer MD. Real-time monitoring of biofilm growth identifies andrographolide as a potent antifungal compound eradicating *Candida* biofilms. *Biofilm*. 2023;5:100134.
136. Nidiry E, Ganeshan G, A N L. Antifungal activity of the extract of *Andrographis paniculata* and andrographolide. *J Pharmacogn Phytochem*. 2015;4:8–10.

